Enrollment completed six months early; $1.5B cash runway into 2029.

Nurix Therapeutics' (NRIX) STAT6 degrader NX-3911 is likely to receive increased recognition after a

Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.

Kymera Therapeutics, Inc. has reported past second-quarter 2026 results showing a reduced net loss of US$61.21 million and lower basic and diluted loss per share of US$0.62, while also completing Phase 2b enrollment for its KT-621 atopic dermatitis trial around six months ahead of schedule and maintaining a cash balance of about US$1.50 billion. Together with the appointment of experienced immunology developer Dr. Terence Rooney as Chief Medical Officer, these clinical, financial, and...

Moby summary of Kymera Therapeutics, Inc.'s Q2 2026 earnings call

Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027. Chief Executive Officer

Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +3.13% and +67.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls

Wall Street analysts reshuffled their bets on Thursday as geopolitical fires, a Fed dissent surprise, and a brutal semiconductor selloff forced some major rating reversals across insurance, gaming, tech, and energy stocks.

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.

American Express, Biogen upgraded: Wall Street's top analyst calls